Daspone
Gel · trading as Dapsone
To Be Discontinued Active (discontinuing) — Day 48
High impact — Sole-source drug with no supply currently available from this manufacturer.
FDA shortage record
- Substance
- Daspone
- Brand name
- Dapsone
- Manufacturers / suppliers
-
- Amneal Pharmaceuticals NY LLC
- Amneal Pharmaceuticals
- Dosage form
- Gel
- Presentation
- Dapsone, Gel, 7.5% (NDC 69238-1627-6)
- Route(s)
- TOPICAL
- Therapeutic category
- Dermatology
- Package NDC
69238-1627-6- Initially posted
- 03/27/2026
- Days on shortage list
- 48
- Discontinued
- 03/27/2026
- Current FDA status
- To Be Discontinued
- Shortage entries (current dataset)
- 1 record for Daspone
Reason and context
Discontinuation of the manufacture of the drug
Manufacturer contact
Per the FDA record, the manufacturer's contact for supply inquiries is 866-525-7270.
If you're affected by this shortage
- Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
- Ask your pharmacy to check supply across multiple wholesalers and other branches.
- Check current pharmacy pricing and availability via GoodRx (affiliate link).
- Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.
Sources
- FDA Drug Shortages database, accessed via the openFDA Drug Shortages API.
- FDA Structured Product Label (SPL set ID
fba0b181-077a-4667-bde1-cf9592f120c2). - FDA UNII identifier:
8W5C518302. - See the Drug Shortage Tracker methodology for sourcing, update cadence, normalization rules, and limits.
Important
This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.